Tagged with pricing

BIO Chair Ted Love on IRA, US Election Outcomes & the Biosecure Act
Gilead CEO Named New PhRMA Board Chair; Inherits a Litany of Challenges
US Drug Pricing and Reimbursement: Players, Payers, PBMs, and Prospects
The IRA & Uncertain Times for US Pharma
Cracking the Elusive GtN Code in Pharma Pricing
Pharma Braces for Widespread Impact of US IRA
First Ten Drugs Subject to Medicare Pricing Negotiations
German Stakeholders Ramp up Critique of Proposed Healthcare Reform
Betting the Bottom Dollar on AI in Pricing & Market Access
Four Insights from Amgen CEO Bob Bradway
Merck’s IRA Lawsuit Comes Under Fire from Own Shareholders
Inside Belgium’s Drug Reimbursement Reform
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here